A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm , Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)
Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 18 Apr 2018
At a glance
- Drugs Nalbuphine (Primary)
- Indications Prurigo nodularis
- Focus Therapeutic Use
- Acronyms PRISM
- Sponsors Trevi Therapeutics
- 10 Apr 2018 Status changed from planning to not yet recruiting.
- 09 Nov 2016 New trial record
- 13 Oct 2016 According to Trevi Therapeutics media release, this study is intended to start in 2017.